Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?

A poor PDAC prognosis is due to a lack of effective treatment and late diagnosis. The early detection of PDAC could significantly decrease mortality and save lives. Idealbiomarkers for PDAC should be cost-effective, detectable in easily accessible biological material, and present in sufficient conce...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Monika Kapszewicz, Ewa Małecka-Wojciesko
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	PDAC biomarkers early diagnostic ELISA Medicine R
Acceso en línea:	https://doaj.org/article/8e26b0509e3a4e1394445cb12f6e1682
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8e26b0509e3a4e1394445cb12f6e1682
record_format	dspace
spelling	oai:doaj.org-article:8e26b0509e3a4e1394445cb12f6e16822021-11-25T18:03:05ZSimple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?10.3390/jcm102254632077-0383https://doaj.org/article/8e26b0509e3a4e1394445cb12f6e16822021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/22/5463https://doaj.org/toc/2077-0383A poor PDAC prognosis is due to a lack of effective treatment and late diagnosis. The early detection of PDAC could significantly decrease mortality and save lives. Idealbiomarkers for PDAC should be cost-effective, detectable in easily accessible biological material, and present in sufficient concentration in the earliest possible phase of the disease. This review addresses newly selected, simple protein biomarkers—new ones such as thrombospondin-2, insulin-linked binding protein 2, lysophosphatidic acid, and autotaxin and conventional ones such as Ca19-9, inflammatory factors, and coagulation factors. Their possible use in the early detection of PDAC, differentiation from benign diseases, prognosis, and treatment response prediction is discussed. We also address the usefulness of possible combinations of biomarkers in diagnostic panels.Monika KapszewiczEwa Małecka-WojcieskoMDPI AGarticlePDAC biomarkersearly diagnosticELISAMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5463, p 5463 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	PDAC biomarkers early diagnostic ELISA Medicine R
spellingShingle	PDAC biomarkers early diagnostic ELISA Medicine R Monika Kapszewicz Ewa Małecka-Wojciesko Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?
description	A poor PDAC prognosis is due to a lack of effective treatment and late diagnosis. The early detection of PDAC could significantly decrease mortality and save lives. Idealbiomarkers for PDAC should be cost-effective, detectable in easily accessible biological material, and present in sufficient concentration in the earliest possible phase of the disease. This review addresses newly selected, simple protein biomarkers—new ones such as thrombospondin-2, insulin-linked binding protein 2, lysophosphatidic acid, and autotaxin and conventional ones such as Ca19-9, inflammatory factors, and coagulation factors. Their possible use in the early detection of PDAC, differentiation from benign diseases, prognosis, and treatment response prediction is discussed. We also address the usefulness of possible combinations of biomarkers in diagnostic panels.
format	article
author	Monika Kapszewicz Ewa Małecka-Wojciesko
author_facet	Monika Kapszewicz Ewa Małecka-Wojciesko
author_sort	Monika Kapszewicz
title	Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?
title_short	Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?
title_full	Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?
title_fullStr	Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?
title_full_unstemmed	Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?
title_sort	simple serum pancreatic ductal adenocarcinoma (pdac) protein biomarkers—is there anything in sight?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/8e26b0509e3a4e1394445cb12f6e1682
work_keys_str_mv	AT monikakapszewicz simpleserumpancreaticductaladenocarcinomapdacproteinbiomarkersisthereanythinginsight AT ewamałeckawojciesko simpleserumpancreaticductaladenocarcinomapdacproteinbiomarkersisthereanythinginsight
_version_	1718411693513506816

Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?

Ejemplares similares